FDA Notice Reclassifying Baxter's Autopheresis-C Includes Special Controls
This article was originally published in The Gray Sheet
Executive Summary
FDA will require equipment failure rates to be reported as part of 510(k) applications for Baxter's Autopheresis-C automated plasmapheresis system, following the device's reclassification from Class III to Class II.